Sanaria
Sanaria

Press / Publications

PRESS

PRESS RELEASES

  • June 13, 2012:Sanaria and the Institute for Bioscience and Biotechnology Research of the University of Maryland College Park Awarded Collaborative, US $3M NIH Phase II Small Business Innovation Research Grant
  • September 8, 2011: Science publishes Sanaria's Research Article, Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity
  • June 29, 2011: Sanaria announces the launch of its Sanaria® Family of Products and Services intended to advance research towards new malaria vaccines, drugs, and diagnostics, and enhanced understanding of malaria pathology and immunobiology
  • February 23, 2010: Sanaria Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research grant to develop a genetically attenuated whole parasite malaria vaccine
  • February 19, 2010: Medicine in Need (MEND) receives $3 million grant from the Bill and Melinda Gates Foundation to apply advanced formulation technologies to the stabilization of new malaria vaccine candidates, including Sanaria's PfSPZ vaccine
  • September 16, 2009: Sanaria receives multi-year U.S. NIH phase II Small Business Innovation Research grant to enhance efficiency and scale-up of its malaria vaccine manufacturing process
  • June 2, 2009: Sanaria receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
  • April 23, 2009: Sanaria and PATH-MVI announce that Phase 1 trial of Sanaria's whole-parasite malaria vaccine called PfSPZ Vaccine to begin; FDA approval for testing in humans watershed moment for unique malaria vaccine approach
  • October 30, 2008: Sanaria and TI Pharma collaborators at Radboud University Nijmegen Medical Centre and Leiden University Medical Centre publish the first report of genetically attenuated P. falciparum sporozoites
  • July 29, 2008: Sanaria and the University of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant
  • May 15, 2008: Sanaria named Maryland's Emerging Company of the Year at the annual Technology Council of Maryland's Tech Awards Celebration
  • January 16, 2008: Sanaria, Top Institute Pharma, Radboud University Nijmegen Medical Centre and Leiden University Medical Center enter into $23.6 million research agreement
  • October 26, 2007: Sanaria, PATH Malaria Vaccine Initiative Open Manufacturing Facility For Producing World's First "Whole-Parasite" Malaria Vaccine
  • January 29, 2007: Sanaria Inc. Receives Multi-Year $3.47 Million U.S. NIH Phase I and Phase II Small Business Innovation Research Grants to Enhance Development of its Malaria Vaccine
  • December 14, 2006: PATH Malaria Vaccine Initiative Announces New Partnership To Accelerate Development of Novel Malaria Vaccine Candidate MVI and Sanaria Inc. to Conduct Initial Safety and Test-of-Concept Trial
  • March 19, 2006: Sanaria CEO, Dr. Stephen L. Hoffman, is the most cited author in the world
  • June 20, 2005: Sanaria Receives NIAID (NIH) award for Development of its Malaria Vaccine
  • May 2, 2005: Sanaria Receives U.S. Army Award for Development of its Malaria Vaccine
  • October 20, 2004: Dr. Stephen L. Hoffman Elected to Membership in the Institute of Medicine of National Academies
  • July 13, 2004: The Institute for One World Health and Sanaria

RELEVANT PUBLICATIONS

NEWS

  • March 2013 - Sanaria's CEO & CSO, Dr. Stephen L. Hoffman, ranked 21st out of the 50 most influential people in vaccines; 50 most influential
  • January 2013 - In collaboration with the Radboud University Nijmegen Medical Center, a high level of controlled human malaria infection (CHMI) was achieved with Sanaria® PfSPZ Challenge paving the way towards the elimination of the need for live mosquito bites to test anti-malarial vaccines and drugs; AJTMH, Healio
  • January 2013 - Sanaria Sr. Director, Dr. Eric James, publishes in Vaccine; Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine
  • January 2013 - Dr. Judith E. Epstein publishes in AJTMH; Taking a Bite out of Malaria: Controlled Human Malaria Infection by Needle and Syringe
  • January 2013 - Sanaria featured in the BBC's news story, A Faster Path to a Possible Malaria Vaccine
  • October 2012 - Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2012
  • June 2012 - Sanaria and the Institute for Bioscience and Biotechnology Research of the University of Maryland College Park Awarded Collaborative, US $3M NIH Phase II Small Business Innovation Research Grant
  • January 2012 - The Sanaria®PfSPZ Vaccine is being assessed in a clinical trial at the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • October 2011 - Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2011
  • September 2011 - Science publishes Sanaria's Research Article, Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity
  • April 2011 - Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, were nominated as one of the Tech Council of Maryland's three finalists for the 2011 Tech Awards for Biotechnology Firm of the Year and Executive of the Year, respectively
  • March 2011 - Sanaria is proud to announce the appointment of Peter F. Billingsley, PhD, Senior Director of Entomology and Quality Systems, to the Editorial Board of the Malaria Journal; more information
  • December 2010 - Bill Shore appeared on Good Morning America to discuss his book The Imaginations of Unreasonable Men: Inspiration, Vision and Purpose in the Quest to End Malaria, featuring Sanaria's CEO Dr. Stephen L. Hoffman and Sanaria Inc.; video
  • December 2010 - Sanaria, in collaboration with the Walter Reed Army Institute of Research and the Center for Disease Control/National Center for Infectious Disease, publish research results in PLoS ONE; Establishment of an In Vitro Assay for Assessing the Effects of Drugs on the Liver Stages of Plasmodium vivax Malaria
  • October 2010 - Sanaria, in collaboration with the University of Maryland School of Medicine and Protein Potential, LLC, publish clinical trial results in PLoS ONE; Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial
  • September 2010 - Sanaria honored to be ranked 15th among all Maryland businesses in The Gazette of Politics and Business Exceptional 53 Business Awards; P & B 53
  • August 2010 - Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, featured in Mental Floss magazine article, The Quest for a Malaria Vaccine and the Man Who Risked Everything to Find It; mentalfloss.com
  • August 2010 - Sanaria's Chief Executive and Scientific Officer, Dr. Stephen L. Hoffman won the Daily Record's Innovator of the Year Award; The Daily Record
  • August 2010 - Sanaria recognized by U.S. Representative Chris Van Hollen for using Recovery Act funding to retain employees and continue its focus on developing a malaria vaccine; POLITICO
  • January 2010 - Dr. David Dolberg, Sanaria's Director of Intellectual Property, is recognized for his contributions to paradigm changing research in cancer; more information
  • January 2010 - Sanaria featured in Volume 6, Issue 1, the January cover, of the Human Vaccines Journal
  • September 2009 - Sanaria ranked 22nd in The Gazette of Politics and Business Exceptional 53 Business Award; Announcement
  • September 2009: Sanaria receives multi-year U.S. NIH phase II Small Business Innovation Research grant to enhance efficiency and scale-up of its malaria vaccine manufacturing process; Press Release
  • July 2009: Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, featured in U.S. News and World Report article, Why a Man Let 2,000 Malaria-Infected Mosquitoes Bite Him; usnews.com
  • June 2009: Sanaria featured in Associated Press article, Pulling malaria from mosquitoes to fight disease
  • April 2009: Sanaria and PATH-MVI announce that Phase 1 trial of Sanaria's whole-parasite malaria vaccine called PfSPZ Vaccine to begin; FDA approval for testing in humans watershed moment for unique malaria vaccine approach; Press Release
  • April 2009: Sanaria wins VIE Award for Best Early-Stage Vaccine Biotech at the World Vaccine Congress Washington; ViE; Press Release
  • December 2008: Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, featured in Esquire magazine
  • July 2008: Sanaria and TI Pharma collaborators publish the first report of genetically attenuated Pf sporozoites; PLoS ONE; Press Release
  • July 2008 Sanaria and the Univ of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant Press Release
  • May 2008: Sanaria named Emerging Company of the Year at the TCM's Tech Awards; TCM; Press Release; Gazette.net
  • March 2008: Sanaria featured in Scientific American; Scientific American
  • January 2008: Sanaria enters into $23.6 million research agreement; Press Release
  • December 2007: Sanaria featured in The New York Times, The Soul of a New Vaccine; and accompanying video, Searching for a Cure for Malaria
  • December 2007: Q & A Session with Sanaria: How to bring a malaria vaccine to market? Larta Institute
  • December 2007: Sanaria CEO, Dr. Stephen L. Hoffman, interviewed on Al Jazeera English's: The Pulse
  • November 2007: Sanaria announced that Adel A. F. Mahmoud, M.D., Ph.D, of the Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University and former President of Merck Vaccines, was elected to Sanaria's Board of Directors
  • October 2007: Sanaria opens Clinical Manufacturing Facility; Press Release: featured in Reuters
  • October 2007: Fred Binka (Sanaria Advisory Board Member) featured in Newsweek,"Giving Globally: The Search for Solutions"
  • July 2007: Sanaria featured in National Geographic magazine, Bedlam in the Blood, Malaria
  • April 2007: Sanaria featured in BBC documentary
  • June 2007: Sanaria signs agreement with University of Maryland Biotechnology Institute
  • June 2007: Sanaria issued U.S. patent
  • June 2007: Sanaria signs agreement with University of Maryland Biotechnology Institute
  • May 2007: Sanaria finalizes agreement with Columbia University to develop genetically attenuated malaria sporozoite vaccine
  • April 2007: Sanaria receives Phase I SBIR grant from NIAID, NIH
  • November 2006: PATH-Malaria Vaccine Initiative receives $29.3M from the BMGF to support Sanaria’s malaria vaccine development efforts
  • November 2006: Sanaria CEO receives award for malariology from American Society of Tropical Medicine and Hygiene
  • October 2006: Sanaria CEO receives honorary doctoral degree from Monmouth University
  • September 2006: Sanaria receives Phase II SBIR grant from NIAID, NIH

 

disclaimer     site map

copyright(c) 2003-2014, Sanaria Inc., all rights reserved
website design by cymaxmedia.com